PDLIM1P4 and Miyoshi myopathy: In a recent study we demonstrated that the overexpression of PDLIM1P4, or the overexpression of PDLIM1P4 and ENSG00000249988, in combination with clinical and genetic risk factors, divided MM patients into different risk groups, associated with distinct levels of progression-free survival (PFS) and overall survival (OS), respectively [13].